Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227290 | 0.86 | LPAR3 (0.46) | GRM4LPAR3LPAR2TYMSALDH1A1 | |
| SCHEMBL4455057 | 0.85 | LPAR3 (0.50) | GRM4LPAR3LPAR2TYMSALDH1A1 | |
| SCHEMBL7785524 | 0.77 | LPAR3 (0.57) | LPAR3LPAR2FDPSS1PR2S1PR4 | |
| SCHEMBL1227298 | 0.75 | FDPS (0.33) | GRM4LPAR3LPAR2FDPS | |
| SCHEMBL9643758 | 0.73 | GRM4 (0.50) | GRM4LPAR3LPAR2TYMSALDH1A1 | |
| SCHEMBL28403595 | 0.73 | LPAR3 (0.47) | LPAR3LPAR2FDPSS1PR4S1PR1 | |
| SCHEMBL1866051 | 0.73 | FDPS (0.36) | ALDH1A1FDPSS1PR2S1PR4S1PR1 | |
| SCHEMBL18438952 | 0.71 | GRM4 (0.48) | GRM4LPAR3LPAR2TYMSALDH1A1 | |
| SCHEMBL3175383 | 0.71 | GRM4 (0.60) | GRM4LPAR3LPAR2TYMSALDH1A1 | |
| SCHEMBL27442316 | 0.70 | LPAR3 (0.53) | LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336362-B2 | Diamondoid compounds | MERCK PATENT GMBH (DE) | 2025-06-17 | — | — | US | disclosed |
| EP-3610868-B1 | AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID DERIVATIVES AND THEIR MEDICAL USE | GRI BIO INC (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2025019953-A1 | ALTERNATING DUAL-ELECTROLYSER SYSTEMS AND METHODS FOR DIRECT AIR CAPTURE (DAC) AND RELEASE OF CO2 | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2025-01-30 | — | — | WO | disclosed |
| US-20240389371-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND COMPOUND | EneCoat Technologies Co., Ltd. (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4394845-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND COMPOUND | Enecoat Technologies Co.,Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-3966871-B1 | DIAMONDOID COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023038050-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND COMPOUND | 株式会社エネコートテクノロジーズ | 2023-03-16 | — | — | WO | disclosed |
| WO-2022178594-A1 | C-REACTIVE PROTEIN INHIBITORS | Baker Heart and Diabetes Institute (AU) | 2022-09-01 | — | — | WO | disclosed |
| US-20220209150-A1 | DIAMONDOID COMPOUNDS | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | ASTELLAS PHARMA INC. (JP) | 2022-03-24 | — | — | US | disclosed |
| US-20060269926-A1 | Cyanine dyes substituted by electrophilic groups and/or nucleophilic groups including merocyanine, methine, oxazoline, oxonol, selenazole fluorescent, imidazoline, quinoline, indole, reactive and cationic dyes; labeling reagents for proteins and nucleic acids; genetic probes; amplification; hybridization | ENZO LIFE SCIENCES, INC. | 2006-11-30 | — | — | US | disclosed |
| EP-1530577-B1 | ORGANOPHOSPHOROUS COMPOUNDS HAVING POLYSULFIDE BRIDGE | CENTRE NAT RECH SCIENT (FR) | 2006-03-01 | — | — | EP | disclosed |
| US-20060014635-A1 | Materials comprising organic groups containing sulphur and phosphorous bonded to a mineral oxide via oxygen atoms | FORESTIERE ALAIN | 2006-01-19 | — | — | US | disclosed |
| US-20050202565-A1 | Luminescent compounds | SETA BIOMEDICALS, LLC | 2005-09-15 | — | — | US | disclosed |
| EP-1530577-A1 | ORGANOPHOSPHOROUS COMPOUNDS HAVING POLYSULFIDE BRIDGE | Centre National de la Recherche Scientifique (FR) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004016630-A1 | ORGANOPHOSPHOROUS COMPOUNDS HAVING POLYSULFIDE BRIDGE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-02-26 | — | — | WO | disclosed |
| US-20020128150-A1 | Materials comprising organic groups containing sulphur and phosphorous bonded to a mineral oxide via oxygen atoms | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-09-12 | — | — | US | disclosed |
| US-5047533-A | Viricides | SRI INTERNATIONAL (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0309491-A1 | ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1989-04-05 | — | — | EP | disclosed |
| WO-1988005438-A1 | ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1988-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060269926-A1 | Cyanine dyes substituted by electrophilic groups and/or nucleophilic groups including merocyanine, methine, oxazoline, oxonol, selenazole fluorescent, imidazoline, quinoline, indole, reactive and cationic dyes; labeling reagents for proteins and nucleic acids; genetic probes; amplification; hybridization | OXA1L, ORMDL3, INMT | GRM4 1553/4885LPAR3 4373/4885LPAR2 4842/4885 |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | FTH1, HAMP, TFRC | GRM4 3569/4885LPAR3 2981/4885LPAR2 3887/4885 |
| US-20220209150-A1 | DIAMONDOID COMPOUNDS | CCND2, ZYX, CCNB2 | GRM4 2447/4885LPAR3 1897/4885LPAR2 1260/4885 |
| US-12336362-B2 | Diamondoid compounds | CCND2, ZYX, CCNB2 | GRM4 2447/4885LPAR3 1897/4885LPAR2 1260/4885 |
| US-20060014635-A1 | Materials comprising organic groups containing sulphur and phosphorous bonded to a mineral oxide via oxygen atoms | AP2M1, OPRM1, AP3M1 | GRM4 461/4885LPAR3 4093/4885LPAR2 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.